Aptose Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Aptose Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Aptose Biosciences Inc Strategy Report
- Understand Aptose Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company that focuses on developing personalized therapies for the treatment of life-threatening cancers including, acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), certain B-cell malignancies, and other hematologic malignancies. The company’s cancer therapeutics pipeline products include HM43239, a myeloid kinome inhibitor (MKI), CG-806, a FLT3/BTK kinase inhibitor; APTO-253, a MYC oncogene inhibitor and APL-581, a dual BET Bromodomain-Kinase Inhibitor. Its small molecule cancer therapeutics pipeline product programs are designed to provide single agent benefit. It operates in Canada and the US and has collaborations with biopharmaceutical companies and healthcare centers for the development and commercialization of its pipeline product programs. Aptose is headquartered in San Diego, California, the US.
Headquarters
Canada
Address
251 Consumers Rd Suite 1105, North York, Ontario, M2J4R3
Website
aptose.com
Telephone
1 647 4799828
No of Employees
35
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APTO (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-22.4%
(2022 vs 2021)
Market Cap*
$20.0M
* As of and is in US$
Aptose Biosciences Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Pipeline products:- |
| CG-806 – For chronic lymphocytic leukemia (CLL) and certain non-Hodgkin’s lymphomas (NHL) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In may, the company entered US$25 common share purchase agreement and registration rights agreement with an institutional investor. |
| 2022 | Others | In May, the company announced fast track status for its HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation from US FDA. |
| 2021 | Contracts/Agreements | In November, the company and Hanmi Pharmaceutical announced their exclusive world wide license agreement for Clinical-Stage Myeloid Kinome Inhibitor HM43239 |
Competitor Comparison
| Key Parameters | Aptose Biosciences Inc | AbbVie Inc | Traws Pharma Inc | Actinium Pharmaceuticals Inc | BeiGene (Beijing) Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United States of America | United States of America | China |
| City | North York | North Chicago | Newtown | New York | Beijing |
| State/Province | Ontario | Illinois | Pennsylvania | New York | Beijing |
| No. of Employees | 35 | 50,000 | 16 | 49 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William G. Rice, Ph.D. | Chairman; President; Chief Executive Officer | Executive Board | 2013 | 64 |
| Fletcher Payne | Chief Financial Officer; Senior Vice President; Chief Business Officer | Senior Management | 2022 | 60 |
| Rafael Bejar, M.D., Ph.D. | Senior Vice President; Chief Medical Officer | Senior Management | 2020 | 52 |
| Philippe Ledru | Chief Commercial Officer; Senior Vice President | Senior Management | 2022 | 56 |
| Robert B. Killion Jr., Ph.D. | Vice President - Chemistry, Manufacture and Control (CMC) | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward